Companies · Biotechnology

PD Theranostics, Inc.

NEW YORK · Biotechnology

Diligence memoA one-page analyst read on PD Theranostics, Inc. — recommendation, valuation, rhythm, risks.
$508K
Total raised · real
2
Rounds
0.4×
Latest step-up
Top 90%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

PD Theranostics, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.74× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era.
At-risk
  • Last raise 4.0 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

PD Theranostics, Inc. is one of 4291 Biotechnology companies tracked from NEW YORK. By capital raised it ranks in the long tail (ahead of 11% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
2
Investors (latest)
2019
Year incorporated
2022-07-12
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$2.5M$5.0M$7.5M$10MPre-Seed · 2022-07-12 Raised $358K (real) Modeled valuation $5.6M (est)$358K$5.6MPre-Seed2022Pre-Seed · 2022-07-12 Raised $358K (real) Modeled valuation $5.6M (est)$358K$5.6MPre-Seed2022Pre-Seed · 2022-07-12 Raised $150K (real) Modeled valuation $2.3M (est)$150K$2.3MPre-Seed2022+$358K+$150KCumulative $866K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$358K · 2022
Pre-Seed extension$358K · 2022
Pre-Seed extension$150K · 2022

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$5.6M
Base estimate est.
$191K
Conservative case
$34.3M
Upside case
$2.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $5.6M · 2022-07-122022Pre-Seed · modeled $5.6M · 2022-07-12Pre-Seed · modeled $2.3M · 2022-07-122022
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
4.0 yr
Elapsed time used
4.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
4.0 yr
On record since
2022
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$508K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.4× of median
This company$150K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$5.6M
Sector median$64.2M

Raised more than 11% of sector peers (real $). Modeled value above 12% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #48 of 185.

This companyCohort peer
$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)TissueMill Technologies LLC · Pre-Seed Raised $1.0M · modeled $18.2M (est)Aldebaran Therapeutics, Inc. · Pre-Seed Raised $800K · modeled $16.3M (est)BullFrog AI Holdings, Inc. · Pre-Seed Raised $866K · modeled $15.4M (est)Vesicle Therapeutics Inc. · Pre-Seed Raised $800K · modeled $14.8M (est)TAUC3 Biologics Ltd · Pre-Seed Raised $839K · modeled $14.4M (est)UCHU Biosensors, Inc. · Pre-Seed Raised $828K · modeled $13.1M (est)BackStop Neural, Inc. · Pre-Seed Raised $884K · modeled $12.9M (est)Virocell Biologics Ltd · Pre-Seed Raised $993K · modeled $12.9M (est)PurCell Bio, Inc · Pre-Seed Raised $841K · modeled $12.6M (est)MicroVizual Inc. · Pre-Seed Raised $750K · modeled $12.0M (est)NeuroX Innovations Inc. · Pre-Seed Raised $1.2M · modeled $11.9M (est)NeuroDex Inc · Pre-Seed Raised $1.3M · modeled $11.8M (est)PD Theranostics, Inc. (this company) Raised $508K · modeled $5.6M (est)PD Theranostics, Inc.
CompanyStageRaised · realValue · estvs peer med.
TissueMill Technologies LLCPre-Seed$1.0M$18.2M5.66×
Aldebaran Therapeutics, Inc.Pre-Seed$800K$16.3M5.05×
BullFrog AI Holdings, Inc.Pre-Seed$866K$15.4M4.78×
Vesicle Therapeutics Inc.Pre-Seed$800K$14.8M4.60×
TAUC3 Biologics LtdPre-Seed$839K$14.4M4.48×
UCHU Biosensors, Inc.Pre-Seed$828K$13.1M4.07×
BackStop Neural, Inc.Pre-Seed$884K$12.9M4.01×
Virocell Biologics LtdPre-Seed$993K$12.9M4.00×
PurCell Bio, IncPre-Seed$841K$12.6M3.91×
MicroVizual Inc.Pre-Seed$750K$12.0M3.73×
NeuroX Innovations Inc.Pre-Seed$1.2M$11.9M3.69×
NeuroDex IncPre-Seed$1.3M$11.8M3.67×
PD Theranostics, Inc. this companyPre-Seed$508K$5.6M1.74×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$358K2022-07-12$2.0M$5.6M90%
Pre-Seed$358K2022-07-12$2.0M$5.6M90%
Pre-Seed$150K2022-07-12$833K$2.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$358K2022-07-12
    • First recorded raise — entered as Pre-Seed.
    • 3 investors on this round.
  2. Pre-Seed$358K2022-07-12
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 3 investors on this round.
  3. Pre-Seed$150K2022-07-12
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.4× smaller than the prior — bridge or down round.
    • 2 investors on this round.
Intelligence
Modeled next raise
$150K
Modeled next size est.range $150K$240K
0.4×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Patrick Gallagher10 other2022-07
Matthew Duffy4 other2022-07
James Ahern3 other2022-07
Matthew Eitner2 other2022-07
Registry & provenance

PD Theranostics, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1830286
SEC CIK
2019
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Voltron Therapeutics, Inc.BiotechnologySeed$9.4M$39.3Mnetwork4 shared operators · same sector
Algorithm Sciences, Inc.BiotechnologySeed$7.2M$1.9Mnetwork3 shared operators · same sector
Carcinotech Ltd.BiotechnologyPre-Seed$508K$3.2Msame sector · same stage
Cardinal Morrisville Biotech LLCBiotechnologyPre-Seed$500K$7.1Msame sector · same stage
Genesis Innovation Group, LLCBiotechnologyPre-Seed$500K$5.5Msame sector · same stage
Oncobiomix Inc.BiotechnologyPre-Seed$500K$3.5Msame sector · same stage
Pupil Bio, Inc.BiotechnologyPre-Seed$500K$4.7Msame sector · same stage
SprinTech, LLCBiotechnologyPre-Seed$500K$3.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Theranos IncBiotechnologyGrowth/Late$24.7B91%
Palladio Biosciences, Inc.BiotechnologySeries B$1.0B85%
PDX Pharmaceuticals, Inc.BiotechnologySeed$68.8M84%
Clinical Sensors, Inc.BiotechnologyPre-Seed$11.0M84%
BioSymetrics, Inc.BiotechnologySeries A$105.6M84%
Diagnostic Biochips, Inc.BiotechnologySeed$33.9M84%
Jupiter Biomedical Research, Inc.BiotechnologyPre-Seed$843K83%
Threat Assessment Imaging, Inc.BiotechnologyPre-Seed$8.3M83%
Frequently asked
How much funding has PD Theranostics, Inc. raised?
PD Theranostics, Inc. has raised approximately $508K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is PD Theranostics, Inc.'s estimated valuation?
Provath's modeled valuation for PD Theranostics, Inc. is approximately $5.6M (modeled range $191K–$34.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is PD Theranostics, Inc. at?
PD Theranostics, Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Tue Jul 12.
What does PD Theranostics, Inc. do and where is it based?
PD Theranostics, Inc. operates in the Biotechnology sector, based in NEW YORK.
Explore related

See where PD Theranostics, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at PD Theranostics, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.